MiniMed 780G System
Medtronic MiniMed, Inc. · Decision date Sep 29, 2026
What did the FDA approve?
The FDA record for P160017/S140 shows approval of a revised protocol for the post-approval study of the MiniMed 780G System, a Medtronic Minimed automated insulin dosing device system with single hormonal control under product code OZP. The supplement was filed on the Normal 180 Day Track No User Fee, with the stated supplement reason "Postapproval Study Protocol." The entry describes a protocol change, not a new approval of the whole system; S140 is a supplement to the original P160017 PMA rather than an original decision in its own right.
The database entry does not specify which protocol elements were revised, nor does it report study size, endpoints, timelines or results. The reported purpose is the revised post-approval study protocol, and this record is not independent proof of safety or clinical effectiveness. How the revision relates to the original PMA's scope cannot be determined from the supplied fields beyond the supplement identifier.
FDA approval order statement
Approval of the revised protocol for the post-approval study (PAS)
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Clinical Chemistry
- Decision date
- Sep 29, 2026
- FDA change category
- Postapproval Study Protocol
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P160017/S140
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic MiniMed, Inc.
- Product code
- OZP
- Decision code
- APPR
- Decision date
- Sep 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Automated insulin dosing device system, single hormonal control.
- Applicant
- Medtronic MiniMed, Inc.
- Product code
- OZP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P160017. Subsequent supplements may change the device or its indications.
FDA decision timeline
P160017 · Original PMA
MiniMed 670G System
P160017/S140 received
Application receipt date recorded by FDA.
P160017/S140 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P160017. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160017
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MiniMed 670G SystemP160017 | Medtronic MiniMed, Inc. | PMA approval | Sep 28, 2016 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic MiniMed, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 18000 Devonshire St., Northridge, CA, 91325
Sources and methodology
- Original FDA record: P160017/S140
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records